NAV

Mebanazine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Mebanazine
DrugBank Accession Number
DB09248
Background

Mebanazine, also known as Actomol, is a monoamine oxidase inhibitor (MAOI) belonging to the hydrazine class of chemicals. It was used in the past as an antidepressant in the 1960s, but has since been discontinued because of its hepatotoxic potential.

Type
Small Molecule
Groups
Withdrawn
Structure
3D
Similar Structures
Weight
Average: 136.198
Monoisotopic: 136.100048394
Chemical Formula
C8H12N2
Synonyms
  • Mebanazine
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

For the treatment of depression.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
1,2-BenzodiazepineThe risk or severity of CNS depression can be increased when Mebanazine is combined with 1,2-Benzodiazepine.
AbaloparatideMebanazine may increase the orthostatic hypotensive activities of Abaloparatide.
AbciximabThe risk or severity of bleeding and hemorrhage can be increased when Mebanazine is combined with Abciximab.
AcarboseMebanazine may increase the hypoglycemic activities of Acarbose.
AcebutololMebanazine may increase the hypotensive activities of Acebutolol.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
International/Other Brands
Actomol

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as benzene and substituted derivatives. These are aromatic compounds containing one monocyclic ring system consisting of benzene.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Not Available
Direct Parent
Benzene and substituted derivatives
Alternative Parents
Alkylhydrazines / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Alkylhydrazine / Aromatic homomonocyclic compound / Hydrazine derivative / Hydrocarbon derivative / Monocyclic benzene moiety / Organic nitrogen compound / Organonitrogen compound / Organopnictogen compound
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
Z5R55CJ4CG
CAS number
65-64-5
InChI Key
HHRZAEJMHSGZNP-UHFFFAOYSA-N
InChI
InChI=1S/C8H12N2/c1-7(10-9)8-5-3-2-4-6-8/h2-7,10H,9H2,1H3
IUPAC Name
(1-phenylethyl)hydrazine
SMILES
CC(NN)C1=CC=CC=C1

References

General References
  1. Gilmour SJ: Clinical trial of mebanazine--a new monoamine oxidase inhibitor. Br J Psychiatry. 1965 Sep;111(478):899-902. [Article]
  2. Barker JC, Jan IA, Enoch MD: A controlled trial of mebanazine ('Actomol') in depression. Br J Psychiatry. 1965 Nov;111(480):1095-100. [Article]
  3. Knott F: A preliminary trial of mebanazine in depressive states. J New Drugs. 1965 Nov-Dec;5(6):345-7. [Article]
PubChem Compound
6179
PubChem Substance
310265151
ChemSpider
5944
ChEBI
134728
ChEMBL
CHEMBL1909283
Wikipedia
Mebanazine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility10.6 mg/mLALOGPS
logP1.24ALOGPS
logP1.33Chemaxon
logS-1.1ALOGPS
pKa (Strongest Basic)5.33Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count2Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area38.05 Å2Chemaxon
Rotatable Bond Count2Chemaxon
Refractivity53.93 m3·mol-1Chemaxon
Polarizability15.65 Å3Chemaxon
Number of Rings1Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleYesChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-0ab9-8900000000-1946646b9b89fe858995
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0a4i-1900000000-f488b2baa10b30d1042c
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0uxr-0900000000-e06398c60f054aad8925
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0a4i-4900000000-7c68bfd0851c491ba5fd
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0a4i-4900000000-7af0b8c5b81e187078e0
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0fb9-9400000000-4900972a3613361c3e99
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0006-9100000000-8523e284a0f8eea12dbb
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-124.93085
predicted
DeepCCS 1.0 (2019)
[M+H]+128.17235
predicted
DeepCCS 1.0 (2019)
[M+Na]+137.08507
predicted
DeepCCS 1.0 (2019)

Drug created at October 24, 2015 03:57 / Updated at February 21, 2021 18:52